Developing next generation immunotherapies.

Immunotherapies for bladder cancer using innovative approaches.

About Zysthera

Home

About

Zysthera is developing next generation immunotherapy for bladder cancer.

How it Works

The Problem

A worldwide Bacillus Calmette-Guérin shortage of 15-20% (1) is impacting approx. 30’000 bladder cancer patients per year for 10 years now.

This has resulted in:

2.9 times higher risk of recurrence (2)

4.7 times higher rate of cystectomy (2)

3.8 times higher costs (2)

(1) Harvey et al, Urol Oncol 2022

(2) Ourfali et al, Eur Urol Focus 2021

The Solution

Members of ZYSTHERA have co-developed the clinical implementation of a new immunotherapeutic for the treatment of bladder cancer. ZYSTHERA aims to initiate phase III studies with the aim to close the Bacillus Calmette-Guérin shortage as soon as possible.

The Method

Details to follow...

Further Information

Bladder Cancer

Bladder cancer is one of the most common cancer types.

Every year it impacts the lives of 575'000 patients. 200’000 patients die every year. The shortage of Bacillus Calmette-Guérin is impacting these patients that could live longer.

Our Team

Cyrill A. Rentsch

CEO

Professor of Urology at the University Hospital Basel (USB), Switzerland. National and international scientific track record in Bacillus Calmette-Guérin therapy and bladder cancer.

Sezai Taskin

CBO

Over 20 years of experience in the pharmaceutical industry with leadership roles in strategic development and commercialization.

Frédéric Birkhäuser

CMO

Assistant professor of Urology. Urologist at the Hirslanden Clinic St. Anna Lucerne and Consultant Urologist at the Universities of Bern and Basel. Research fellowship in immuno-oncology at the Institute of Urologic Oncology, University of California Los Angeles, UCLA. Investigator in pre-clinical and clinical trials, namely for Bacillus Calmette-Guérin therapy and bladder cancer.